To validate eIF2Bα as potential candidate for the treatment of CRC in a physiological context, we used the murine WT, A, AK and LAKTP organoids transduced with one or two independent doxycycline-inducible shRNAs against mouse Eif2b1 (shEif2b1-1 and shEif2b1-2) or, as control, a non-targeting shRNA (shCTRL). Here, EIF2B1 is linked to colorectal carcinoma.